2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Profiling, Treatment Considerations, Therapy Sequence, Biological Therapies, Transplantation, (CAR)-T Cell Therapies, Non-Biological Therapies, Chemotherapy, Biological Processes, Pathogenesis, Genomics, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Hemoglobinopathies, Sickle Cell Disease, Immunology, Immunodeficiency, Neutropenia, White Blood Cell Disorders, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, B Cell Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, AML, MDS, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Survivorship, Study Population, Human, Adult, Pediatric
PAPER

6061 Prognostic significance of loss of Y chromosome in male patients undergoing allogeneic hematopoietic stem cell transplantation

Xueyao Li, Xianjing Zhang2, Yigeng Cao II, MD, PhD3, Erlie Jiang, MD4
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China

Background:

Loss of Y chromosome (LOY) is a common age-related clonal hematopoietic alteration that frequently co-occurs with clonal hematopoiesis of indeterminate potential and has been associated with adverse clinical outcomes. In allogeneic hematopoietic stem cell transplantation (allo-HSCT), LOY may additionally attenuate H-Y antigen–mediated graft-versus-leukemia (GVL) effects. We aimed to investigate the impact of LOY on clinical outcomes after allo-HSCT. 

Methods:

A retrospective analysis was conducted for 1119 patients who underwent allo-HSCT at the Institute of Hematology and Blood Disease Hospital from January 2022 to June 2025. 

Results:

Among the 1,119 patients, 48 (4.29%) had LOY at initial diagnosis. The LOY group showed a inferior overall survival (OS) compared with the Y-present group (3-year OS, 58.6% vs. 78.0%; P = 0.051). Relapse-free survival (RFS) was significantly inferior in the LOY group (3-year RFS, 57.1% vs. 71.4%; P = 0.006), and the cumulative incidence of relapse (CIR) was significantly higher (3-year CIR, 23.2% vs. 15.0%; P = 0.032). No significant difference in the cumulative incidence of grade II–IV acute graft-versus-host disease (aGVHD) was observed between the LOY and Y-present groups (20.8% vs. 29.5%; P = 0.196). Among patients who underwent female-to-male allo-HSCT, those in the LOY group had significantly inferior OS and RFS compared with those in the Y-present group (3-year OS, 45.0% vs. 77.8%; P = 0.006; 3-year RFS, 46.7% vs. 73.3%; P = 0.002). The LOY group also showed a trend toward a higher CIR (3-year CIR, 26.7% vs. 13.6%; P = 0.084). No significant difference in the cumulative incidence of grade II–IV aGVHD was observed between the two groups (20.0% vs. 29.4%; P = 0.568). In contrast, LOY was not significantly associated with clinical outcomes among patients who underwent male-to-male allo-HSCT. 

Conclusion:

LOY at initial diagnosis in male patients was associated with an increased risk of relapse and adverse survival outcomes after allo-HSCT, potentially due to an attenuated GVL effect. The adverse prognostic impact of LOY was predominantly observed in male recipients with female donors, suggesting that the donor-recipient sex combination may modulate LOY-associated post-transplant immune effects and clinical outcomes.

Xueyao Li: No relevant conflicts of interest to declare.